Form 4: Fractyl Health Director Marc Elia Granted Stock Options as Compensation

Fractyl Health, Inc. director Marc Elia was granted 22,500 stock options with an exercise price of $2.27 as part of his compensation for board service.

Summary

• Marc Elia, a Director of Fractyl Health, Inc. (GUTS), was granted 22,500 stock options.
• The options have an exercise price of $2.27 per share.
• The grant date for these options was June 11, 2025.
• These options were awarded as compensation for his service on the Issuer's board of directors, consistent with the Issuer's non-employee director compensation policy.
• The stock options will vest in a single installment on the earlier of the date of the next annual meeting of stockholders or the first anniversary of the grant date (approximately June 11, 2026).
• Vesting is contingent upon his continued service as a non-employee director through the vesting date.
• The options have an expiration date of June 10, 2035.

Sentiment

Score: 7

Explanation: The document reports a routine compensation event for a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard corporate governance.

Positives

• The grant aligns the director's interests with shareholders through equity compensation, incentivizing long-term company performance.
• This compensation is a standard practice for non-employee directors, indicating adherence to established corporate governance policies.
• The vesting conditions incentivize continued service on the board, ensuring stability in governance.

Risks

• The stock options are subject to vesting conditions, specifically continued service on the board of directors as a non-employee director through the vesting date; if service ceases before vesting, the options may be forfeited.
• The value of the options is dependent on the future stock price of Fractyl Health, Inc. exceeding the exercise price of $2.27, meaning there is no guaranteed value if the stock price does not appreciate.

Future Outlook

The stock options are set to vest in a single installment on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date (June 11, 2025), subject to Marc Elia's continued service as a non-employee director.

Industry Context

Granting stock options to non-employee directors is a common practice across various industries, particularly in the biotechnology and healthcare sectors where companies often use equity compensation to attract and retain experienced board members. This aligns the director's financial interests with the long-term performance of the company, a standard corporate governance practice.

Comparison to Industry Standards

• The grant of stock options as compensation for non-employee directors is a widely accepted practice in the U.S. public market, consistent with compensation structures seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their board members, though specific values vary by company size and policy.
• The vesting schedule, typically a single installment or over a short period for director grants, is standard, aiming to incentivize continued oversight without creating long-term performance hurdles often associated with executive equity.
• The exercise price being at or above the market price on the grant date is typical for incentive stock options, ensuring that the director benefits only if the company's stock price appreciates.

Corporate Governance

Related Party Transactions

• The grant of stock options to Marc Elia, a director of Fractyl Health, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing long-term stock price appreciation. It also represents a potential for dilution if the options are exercised, though this is typically factored into compensation plans.

Next Steps

• Marc Elia's continued service on the board of directors.
• Vesting of the stock options on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.

Key Dates

Keywords

Fractyl Health, GUTS, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Non-Employee Director, Executive Compensation, Corporate Governance